Page last updated: 2024-12-05
2,3,4-Trihydroxybenzoic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 11874 |
| CHEMBL ID | 220779 |
| CHEBI ID | 88714 |
| SCHEMBL ID | 77708 |
Synonyms (52)
| Synonym |
|---|
| pyrogallolcarboxylate |
| 4-10-00-01971 (beilstein handbook reference) |
| unii-ad1id2jf5o |
| ad1id2jf5o , |
| nsc27436 |
| pyrogallolcarboxylic acid |
| nsc-27436 |
| benzoic acid,3,4-trihydroxy- |
| 610-02-6 |
| 2,4-trihydroxybenzoate |
| 4-pyrogallolcarboxylic acid |
| 2,4-trihydroxybenzene carboxylic acid |
| 2,4-trihydroxybenzoic acid |
| brn 2210807 |
| 2,3,4-trihydroxybenzene carboxylic acid |
| 2,3,4-trihydroxybenzoate |
| benzoic acid, 2,3,4-trihydroxy- |
| 2,3,4-trihydroxybenzoic acid |
| einecs 210-205-9 |
| nsc 27436 |
| inchi=1/c7h6o5/c8-4-2-1-3(7(11)12)5(9)6(4)10/h1-2,8-10h,(h,11,12 |
| 2,3,4-trihydroxybenzoic acid, 97% |
| OPREA1_870375 |
| AC-11254 |
| CHEMBL220779 , |
| chebi:88714 , |
| bdbm50205386 |
| P0571 |
| pyrogallol-4-carboxylic acid |
| AKOS004114674 |
| F1995-0241 |
| 2,3,4-trihydroxy-benzoic acid |
| benzoic acid, trihydroxy- |
| 2,3,4-trihydroxybenzoic acid hydrate |
| FT-0609392 |
| S12282 |
| S6018 |
| SCHEMBL77708 |
| 2,3,4-trihydroxybenzenecarboxylic acid |
| pyrogallic acid-4-carboxylic acid |
| BRRSNXCXLSVPFC-UHFFFAOYSA-N |
| W-105210 |
| AS-8189 |
| DTXSID20209851 |
| mfcd00002447 |
| 2,3,4-trihydroxybenzoicacid |
| trihydroxybenzoic acid |
| CS-W017709 |
| Q27160621 |
| SY038924 |
| HY-W016993 |
| PD124114 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| hydroxybenzoic acid | Any benzoic acid carrying one or more phenolic hydroxy groups on the benzene ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (4)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| P-selectin | Homo sapiens (human) | IC50 (µMol) | 11.8000 | 5.0000 | 5.0000 | 5.0000 | AID280291 |
| E-selectin | Homo sapiens (human) | IC50 (µMol) | 500.0000 | 0.0200 | 2.2133 | 6.6000 | AID280289 |
| Autoinducer 2-binding periplasmic protein LuxP | Vibrio harveyi | IC50 (µMol) | 61.0000 | 2.0000 | 3.0000 | 4.0000 | AID314588 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (23)
Molecular Functions (15)
Ceullar Components (11)
Bioassays (10)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID280289 | Inhibition of human E-selectin after 2 hrs | 2007 | Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6 | Rational design of novel, potent small molecule pan-selectin antagonists. |
| AID280296 | Inhibition of attachment of HL60 cells to P-selectin at 109 uM after 5 mins | 2007 | Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6 | Rational design of novel, potent small molecule pan-selectin antagonists. |
| AID1363739 | Inhibition of Influenza A (A/California/04/2009) (H1N1) clinical isolate N-terminal truncated PA endonuclease using 5'-FAM/3-TAMRA quencer labeled 17-mer ssDNA-oligo as substrate measured over 45 mins by FRET assay | 2018 | Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22 | Structure-Activity Relationships in Metal-Binding Pharmacophores for Influenza Endonuclease. |
| AID280293 | Inhibition of human L-selectin after 2 hrs | 2007 | Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6 | Rational design of novel, potent small molecule pan-selectin antagonists. |
| AID314590 | Growth inhibition of Vibrio harveyi assessed as time required to double bacterial growth relative to control | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5 | Pyrogallol and its analogs can antagonize bacterial quorum sensing in Vibrio harveyi. |
| AID314588 | Antagonist activity at LuxP receptor in Vibrio harveyi MM32 assessed as inhibition of autoinducer-2-mediated quorum sensing after 3 to 4 hrs | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5 | Pyrogallol and its analogs can antagonize bacterial quorum sensing in Vibrio harveyi. |
| AID280291 | Inhibition of human P-selectin after 2 hrs | 2007 | Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6 | Rational design of novel, potent small molecule pan-selectin antagonists. |
| AID280295 | Inhibition of attachment of HL60 cells to E-selectin at 109 uM after 5 mins | 2007 | Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6 | Rational design of novel, potent small molecule pan-selectin antagonists. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 23.30
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.30) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||